Guggenheim Capital’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1M Buy
14,173
+4,505
+47% +$243K 0.01% 1021
2026
Q1
$505K Sell
9,668
-226
-2% -$13.6K ﹤0.01% 1203
2025
Q4
$582K Sell
9,894
-899
-8% -$54.6K ﹤0.01% 1206
2025
Q3
$600K Buy
10,793
+503
+5% +$26.9K ﹤0.01% 1108
2025
Q2
$529K Buy
10,290
+118
+1% +$5.93K ﹤0.01% 1157
2025
Q1
$596K Sell
10,172
-578
-5% -$39.2K 0.01% 1115
2024
Q4
$774K Sell
10,750
-1,511
-12% -$111K 0.01% 1026
2024
Q3
$980K Sell
12,261
-572
-4% -$43K 0.01% 1115
2024
Q2
$919K Sell
12,833
-3,022
-19% -$222K 0.01% 1172
2024
Q1
$1.12M Buy
15,855
+231
+1% +$16.5K 0.01% 1134
2023
Q4
$1.21M Sell
15,624
-156
-1% -$10.3K 0.01% 1062
2023
Q3
$1.07M Sell
15,780
-249
-2% -$19.7K 0.01% 1083
2023
Q2
$1.31M Sell
16,029
-2,831
-15% -$228K 0.01% 1037
2023
Q1
$1.4M Sell
18,860
-31,349
-62% -$2.42M 0.01% 1011
2022
Q4
$4.16M Sell
50,209
-12,623
-20% -$1M 0.04% 591
2022
Q3
$4.46M Sell
62,832
-7,860
-11% -$679K 0.04% 548
2022
Q2
$6.13M Sell
70,692
-4,188
-6% -$392K 0.05% 460
2022
Q1
$8.11M Sell
74,880
-8,540
-10% -$881K 0.05% 462
2021
Q4
$10.8M Buy
83,420
+21,092
+34% +$2.59M 0.06% 401
2021
Q3
$7.55M Sell
62,328
-1,036
-2% -$126K 0.05% 497
2021
Q2
$7.13M Sell
63,364
-1,652
-3% -$174K 0.04% 526
2021
Q1
$6.21M Sell
65,016
-4,360
-6% -$398K 0.04% 536
2020
Q4
$5.51M Sell
69,376
-14,352
-17% -$1.04M 0.03% 542
2020
Q3
$5.18M Sell
83,728
-11,352
-12% -$738K 0.04% 508
2020
Q2
$6.28M Buy
95,080
+9,948
+12% +$596K 0.05% 432
2020
Q1
$4.04M Sell
85,132
-15,360
-15% -$768K 0.04% 521
2019
Q4
$5.51M Buy
100,492
+21,976
+28% +$1.15M 0.04% 581
2019
Q3
$3.84M Sell
78,516
-47,092
-37% -$2.36M 0.03% 724
2019
Q2
$6.55M Buy
125,608
+26,620
+27% +$1.34M 0.05% 463
2019
Q1
$4.91M Sell
98,988
-4,440
-4% -$200K 0.04% 630
2018
Q4
$3.74M Sell
103,428
-23,640
-19% -$987K 0.03% 723
2018
Q3
$6.48M Sell
127,068
-17,896
-12% -$793K 0.04% 571
2018
Q2
$5.36M Sell
144,964
-152,396
-51% -$5.82M 0.04% 677
2018
Q1
$11.2M Sell
297,360
-15,684
-5% -$554K 0.03% 641
2017
Q4
$10.1M Sell
313,044
-104,684
-25% -$3.33M 0.02% 682
2017
Q3
$12.6M Buy
417,728
+37,580
+10% +$1.12M 0.03% 602
2017
Q2
$11.2M Sell
380,148
-4,756
-1% -$130K 0.03% 637
2017
Q1
$9.78M Sell
384,904
-9,420
-2% -$243K 0.03% 682
2016
Q4
$10.1M Buy
394,324
+94,432
+31% +$2.48M 0.03% 660
2016
Q3
$8.21M Sell
299,892
-22,376
-7% -$615K 0.03% 756
2016
Q2
$9.09M Sell
322,268
-52,908
-14% -$1.36M 0.03% 717
2016
Q1
$8.87M Sell
375,176
-116,188
-24% -$2.56M 0.03% 742
2015
Q4
$11.1M Buy
491,364
+103,088
+27% +$2.35M 0.03% 718
2015
Q3
$8.97M Sell
388,276
-4,484
-1% -$112K 0.03% 800
2015
Q2
$9.67M Buy
392,760
+43,980
+13% +$1.1M 0.02% 844
2015
Q1
$8.74M Buy
348,780
+78,096
+29% +$1.86M 0.02% 911
2014
Q4
$6.25M Buy
270,684
+38,276
+16% +$876K 0.02% 1028
2014
Q3
$5.43M Buy
232,408
+920
+0.4% +$21.6K 0.01% 1158
2014
Q2
$5.36M Sell
231,488
-78,324
-25% -$1.73M 0.01% 1145
2014
Q1
$6.61M Buy
309,812
+50,576
+20% +$1.14M 0.02% 998
2013
Q4
$6.14M Sell
259,236
-56,080
-18% -$1.22M 0.02% 1000
2013
Q3
$6.31M Buy
315,316
+245,028
+349% +$4.65M 0.02% 992
2013
Q2
$1.21M Buy
+70,288
New +$1.17M 0.01% 1898

Other funds holding TECH

Guggenheim Capital's TECH Position: Q2 2026 in Review

Guggenheim Capital increased its Bio-Techne (TECH) stake by 47% in Q2 2026, buying an estimated $243K and bringing the position to 14,173 shares worth $1M. The position accounts for 0.01% of the portfolio, ranked #1021.

Guggenheim Capital first reported a position in TECH in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.6M in Q3 2017. 593 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Guggenheim Capital held 14,173 shares of Bio-Techne worth $1M as of Q2 2026.
  • Guggenheim Capital bought 4,505 Bio-Techne shares in Q2 2026, an estimated $243K.
  • Bio-Techne made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1021 holding.
  • Guggenheim Capital first reported a position in Bio-Techne in Q2 2013 and has held it in 53 quarters since.
  • Guggenheim Capital's Bio-Techne position peaked at $12.6M in Q3 2017.
  • 593 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.